Recovery of [14C]-equivalents from female B6C3F1 mice following administration of [14C]trans-methyl styryl ketone
| Route of Administration | Percentage of Radioactive Dose Recovered‡ | ||||
|---|---|---|---|---|---|
| Urine | Feces | Exhaled† | Trap and Skin Site§ | Total Recovery | |
| Intravenous (20 mg/kg) | 92.4 ± 6.0 | 3.5 ± 2.9 | 1.2 ± 0.8 | – | 97.1 ± 5.3 |
| Oral (200 mg/kg) | 94.4 ± 3.4 | 1.2 ± 0.2 | 0.3 ± 0.04 | – | 95.9 ± 3.6 |
| Topical (250 mg/kg) | 36.1 ± 10.8 | 3.2 ± 1.9 | 0.8 ± 0.4 | 57.1 ± 5.5 | 97.2 ± 7.6 |
‡ Mean % of dose ± SD, N = 3; oral and intravenous studies were conducted for 48 hr, while the dermal study was conducted for 72 hr.
† Includes [14C]CO2 and [14C]organic equivalents exhaled and trapped.
§ Includes percutaneous skin trap, activated charcoal, and skin at site of MSK application.